Evidence map›Paper›PMID 35897914›Full record

ArticleMolecules (Basel, Switzerland)2022

Synthesis and Biological Evaluation of Novel Allobetulon/Allobetulin-Nucleoside Conjugates as AntitumorAgents.

Yanli Wang, Xiaowan Huang, Xiao Zhang, Jingchen Wang, Keyan Li, Guotao Liu, Kexin Lu, Xiang Zhang, Chengping Xie, Teresa Zheng and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Yanli WangSchool of Medicine, Huanghe Science and Technology College, Zhengzhou 450063, China.
Xiaowan HuangHigh & New Technology Research Center, Henan Academy of Science, Zhengzhou 450002, China.
Xiao ZhangBGI College & Henan Institute of Medical and Pharmaceutical Science, Zhengzhou University, Zhengzhou 450052, China.
Jingchen WangBGI College & Henan Institute of Medical and Pharmaceutical Science, Zhengzhou University, Zhengzhou 450052, China.
Keyan LiNational Health Commission Key Laboratory of Birth Defect Prevention, Henan Institute of Reproductive Health Science and Technology, Zhengzhou 450002, China.
Guotao LiuNational Health Commission Key Laboratory of Birth Defect Prevention, Henan Institute of Reproductive Health Science and Technology, Zhengzhou 450002, China.
Kexin LuBGI College & Henan Institute of Medical and Pharmaceutical Science, Zhengzhou University, Zhengzhou 450052, China.
Xiang ZhangHigh & New Technology Research Center, Henan Academy of Science, Zhengzhou 450002, China.
Chengping XieHigh & New Technology Research Center, Henan Academy of Science, Zhengzhou 450002, China.
Teresa ZhengDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7568, USA.
Yung-Yi ChengDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7568, USA.ORCID 0000-0001-7473-2835
Qiang WangSchool of Medicine, Huanghe Science and Technology College, Zhengzhou 450063, China.
Zhengzhou University · CNNational Health and Family Planning Commission · CNUniversity of North Carolina at Chapel Hill · USHenan Academy of Sciences · CN

Funding

Basal Research Fund of Henan Academy of Sciences 220602063Basal Research Fund of the National Health Commission Key Laboratory of Birth Defect Prevention JBKY2022012Science and Technology Research Project of Henan Province 222102310400
6 · The paper itself

Abstract

Allobetulin is structurally similar tobetulinic acid, inducing the apoptosis of cancer cells with low toxicity. However, both of them exhibited weak antiproliferation against several tumor cell lines. Therefore, the new series of allobetulon/allobetulin-nucleoside conjugates

Indexed as

Antineoplastic AgentsCisplatinApoptosisCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMolecular StructureNucleosidesOxaliplatinStructure-Activity RelationshipAntineoplastic AgentsCisplatinNucleosidesOxaliplatinallobetulinantitumor activityapoptosisconjugatesnucleosidespentacyclic triterpene

Identifiers

PMID35897914
PMCPMC9329720
OpenAlexW4287838315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.